Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, do not respond to commonly used therapies.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.